Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer

Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)

(2013) Wasaburo Koizumi et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Management of gastric cancer in Asia: resource-stratified guidelines

(2013) Lin Shen et al.   LANCET ONCOLOGY

Docetaxel, Cisplatin and Fluorouracil (DCF) Regimen Compared with Non-Taxane-Containing Palliative Chemotherapy for Gastric Carcinoma: A Systematic Review and Meta-Analysis

(2013) Xiao-Long Chen et al.   PLoS One

The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer

(2012) Irit Ben Aharon et al.   ANTI-CANCER DRUGS

Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC)

(2012) S. Keskin et al.   Clinical & Translational Oncology

Guidelines for the management of oesophageal and gastric cancer

(2011) W. H. Allum et al.   GUT

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

(2010) N C Tebbutt et al.   BRITISH JOURNAL OF CANCER

Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer

(2010) Michael J. Overman et al.   CANCER

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

(2009) Narikazu Boku et al.   LANCET ONCOLOGY

The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma

(2009) Nuriye Yıldırım Özdemir et al.   MEDICAL ONCOLOGY

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

(2008) Wasaburo Koizumi et al.   LANCET ONCOLOGY